Analisis saham Lazard pertanyakan target pertumbuhan meski ada imbal hasil dividen

Sebuah analisis investasi menyoroti kekhawatiran mengenai posisi kompetitif dan prospek pendapatan Lazard.

Laporan tersebut mencatat bahwa Lazard tidak memiliki keunggulan kompetitif yang bertahan lama dalam perbankan investasi atau manajemen aset. Laporan ini menunjukkan bisnis perusahaan yang sangat siklikal, dengan penurunan pendapatan baru-baru ini yang terkait dengan aktivitas pasar modal. Perusahaan telah menetapkan target untuk melipatgandakan pendapatan tahunan pada tahun 2030, namun analisis tersebut mempertanyakan apakah sejarah pertumbuhan yang rendah dan momentum operasional yang lemah mendukung target tersebut. Meskipun terdapat imbal hasil dividen sebesar 4,3%, rekomendasinya adalah untuk menahan saham karena terbatasnya prospek pertumbuhan dan penilaian premium dibandingkan sektornya.

Artikel Terkait

NewLake Capital Partners maintains a strong buy rating with a nearly 12 percent dividend yield.

Dilaporkan oleh AI

BNP Paribas analyst Kumar Rakesh has cautioned investors against viewing largecap Indian IT stocks as a straightforward value play. He points to weak FY27 guidance, AI-led disruptions, and stalled client spending as major challenges. Buybacks and dividends offer some support, but earnings risks remain high.

HCL Technologies shares dropped more than 9% following disappointing March quarter results and cautious FY27 guidance. While year-on-year profit and revenue grew, sequential declines in constant currency and margins fell short of expectations. Brokerages including JPMorgan and HSBC cut their target prices in response.

Dilaporkan oleh AI

Allianz SE delivered a strong start to 2026 during its first quarter earnings call on May 13. Chief Financial Officer Claire-Marie Coste-Lepoutre highlighted continued progress across key strategic areas. The company reaffirmed its full year outlook despite elevated market volatility.

An analyst has named Aris Mining (NYSE:ARIS) as the top pick in the gold sector, projecting significant production growth and financial gains. The company aims to quadruple output by 2031, with EBITDA expected to triple by 2027 under high gold price assumptions. The stock carries a price target of $38 for 2027, suggesting over 100% upside.

Dilaporkan oleh AI

Sun Pharmaceutical Industries posted robust revenue and profit increases for the March quarter. The company noted pressure on EBITDA margins due to higher investments and reduced milestone income. Outlook for the next fiscal year points to steady but moderated expansion.

Situs web ini menggunakan cookie

Kami menggunakan cookie untuk analisis guna meningkatkan situs kami. Baca kebijakan privasi kami untuk informasi lebih lanjut.
Tolak